Short Interest in Hua Medicine (Shanghai) Ltd. (OTCMKTS:HUMDF) Decreases By 8.9%

Hua Medicine (Shanghai) Ltd. (OTCMKTS:HUMDF) was the target of a significant decline in short interest in June. As of June 30th, there was short interest totalling 298,400 shares, a decline of 8.9% from the June 15th total of 327,400 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is currently ∞ days.

Hua Medicine (Shanghai) Price Performance

Shares of Hua Medicine (Shanghai) stock remained flat at C$0.20 on Tuesday. Hua Medicine has a 12-month low of C$0.20 and a 12-month high of C$0.20. The firm has a 50-day simple moving average of C$0.20 and a 200 day simple moving average of C$0.20.

Hua Medicine (Shanghai) Company Profile

Hua Medicine (Shanghai) Ltd. operates as a drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D.